Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Alpha Cognition Inc C.ACOG

Alternate Symbol(s):  ACOGF

Healthcare Biotechnology
Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS.


CSE:ACOG - Post by User

Alpha Cognition Inc > $ACOG.v CEO Michael McFadden talks Alpha-1062 TBI study
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(12)
•••
Comment by ferret_caon Dec 22, 2021 12:25pm
57 Views
Post# 34254866

RE:$ACOG.v CEO Michael McFadden talks Alpha-1062 TBI study

RE:$ACOG.v CEO Michael McFadden talks Alpha-1062 TBI studywell it doesn't look like the interview or presentation did anything to interest prspective buyers or trigger existing shareholders to add shares, still a bit of tax loss selling, the pushing out next results a bit has definitely hurt. I did add a few over the last couple of days but will keep it to a smaller weighting  due to risk and size and my age, lol.

cheers, happy holidays and gl  ferret
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities